Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2005

01.06.2005 | Leading Article

Managing Adverse Events Associated with Botulinum Toxin Type A

A Focus on Cosmetic Procedures

verfasst von: Dr Uwe Wollina, Helga Konrad

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxin A (BTXA) has become a widely used drug in cosmetic dermatology, not only to treat focal hyperhidrosis but also hyperkinetic facial lines, platysma bands, décolleté bands, and other skin features. The spectrum of possible adverse effects of BTXA is broad but fortunately those that have been observed with cosmetic use of this product are generally mild and transient. The major tools for preventing adverse effects from BTXA are knowledge and skill. Use of correct injection techniques is mandatory since most unwanted effects are caused by incorrect technique. Knowledge of the target structures, e.g. the facial and extrafacial muscles, allows physicians to select the optimal dose, time and technique. The most common adverse effects are pain and hematoma. In the periocular region, lid and brow ptosis are important adverse effects. Adverse effects such as pain, hematoma, ecchymosis, and bruising may also occur in the upper and lower face and at extrafacial sites. Other possible adverse effects seen in other indications that the user of BTXA in cosmetic dermatology should be wary of include induction headaches and possible interaction with concomitant medications. Induction of neutralizing antibodies due to cosmetic BTXA treatment has not been observed. This article also outlines recommendations regarding use of BTXA. Of these, the most important for avoiding most unwanted adverse effects are the proper techniques of dilution, storage, and injection, as well as the careful exclusion of patients with any contraindications. Pain, hematoma, ecchymosis, and bruising can be prevented by cooling the skin before and after BTXA injection. Upper lid ptosis may be partly corrected using apraclonidine or phenylephrine eyedrops. If simple rules relating to the indications for and application of BTXA are followed, this is a safe and effective drug in cosmetic dermatology.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Tchitchikine A. Essai d’immunisation par la voie gastrointestinale contre la toxine botulique [letter]. Ann Just Pasteur. 1905; XIX: 335 Tchitchikine A. Essai d’immunisation par la voie gastrointestinale contre la toxine botulique [letter]. Ann Just Pasteur. 1905; XIX: 335
2.
Zurück zum Zitat Schantz EJ, Johnson EA. Botulinum toxin: the story of its development in human disease. Perspect Biol Med. 1997; 40: 317–27PubMed Schantz EJ, Johnson EA. Botulinum toxin: the story of its development in human disease. Perspect Biol Med. 1997; 40: 317–27PubMed
3.
Zurück zum Zitat Brin ME. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997; 20 Suppl. 6: S146–68CrossRef Brin ME. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997; 20 Suppl. 6: S146–68CrossRef
4.
Zurück zum Zitat Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000; 43: 249–59PubMedCrossRef Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000; 43: 249–59PubMedCrossRef
5.
Zurück zum Zitat Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A: Dysport and Botox: assuming a ratio of 4:1. Mov Disord. 1997; 12: 1013–8PubMedCrossRef Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A: Dysport and Botox: assuming a ratio of 4:1. Mov Disord. 1997; 12: 1013–8PubMedCrossRef
6.
Zurück zum Zitat Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998; 64: 6–12PubMedCrossRef Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998; 64: 6–12PubMedCrossRef
7.
Zurück zum Zitat Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002; 72: 459–62PubMed Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002; 72: 459–62PubMed
8.
Zurück zum Zitat Carruthers A, Carruthers J. Cosmetic use of botulinum A exotoxin. Adv Dermatol. 1997; 12: 325-47PubMed Carruthers A, Carruthers J. Cosmetic use of botulinum A exotoxin. Adv Dermatol. 1997; 12: 325-47PubMed
9.
Zurück zum Zitat Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996; 35: 569–72PubMedCrossRef Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996; 35: 569–72PubMedCrossRef
10.
Zurück zum Zitat Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002; 46: 840–9PubMedCrossRef Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002; 46: 840–9PubMedCrossRef
11.
Zurück zum Zitat Lowe NJ, Lask G, Yamauchi P, et al. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol. 2002; 47: 834–40PubMedCrossRef Lowe NJ, Lask G, Yamauchi P, et al. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol. 2002; 47: 834–40PubMedCrossRef
12.
Zurück zum Zitat Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 2003; 29: 7–13PubMedCrossRef Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 2003; 29: 7–13PubMedCrossRef
13.
Zurück zum Zitat Niamtu J. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003; 61: 317–24PubMedCrossRef Niamtu J. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg. 2003; 61: 317–24PubMedCrossRef
14.
Zurück zum Zitat Wilson F. Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times 2001 Mar, 12 Wilson F. Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times 2001 Mar, 12
15.
Zurück zum Zitat Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002; 48: 336–56PubMedCrossRef Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002; 48: 336–56PubMedCrossRef
16.
Zurück zum Zitat Zechmeister M, De Oliveira Dal’Fomo T. Conservation, dilution and storage after dilution. In: Hexsel D, Trinidade de Almeida A, editors. Cosmetic use of botulinum toxin. Porto Alegre: AGE Editoria, 2002: 43–4 Zechmeister M, De Oliveira Dal’Fomo T. Conservation, dilution and storage after dilution. In: Hexsel D, Trinidade de Almeida A, editors. Cosmetic use of botulinum toxin. Porto Alegre: AGE Editoria, 2002: 43–4
17.
18.
Zurück zum Zitat Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg. 1998; 24: 1189–94PubMedCrossRef Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg. 1998; 24: 1189–94PubMedCrossRef
19.
Zurück zum Zitat Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg. 1998; 24: 1249–54PubMedCrossRef Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg. 1998; 24: 1249–54PubMedCrossRef
20.
Zurück zum Zitat Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX (R)-related anaphylaxis? J Forensic Sci. In press Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX (R)-related anaphylaxis? J Forensic Sci. In press
21.
Zurück zum Zitat Cohen DE, Kaufmann JM. Hypersensitivity reactions to products and devices in plastic surgery. Facial Plast Surg Clin N Am. 2003; 11: 253–65CrossRef Cohen DE, Kaufmann JM. Hypersensitivity reactions to products and devices in plastic surgery. Facial Plast Surg Clin N Am. 2003; 11: 253–65CrossRef
22.
Zurück zum Zitat Cox NH, Duffey P, Royle J. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol. 1999; 40: 263–4PubMedCrossRef Cox NH, Duffey P, Royle J. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol. 1999; 40: 263–4PubMedCrossRef
23.
Zurück zum Zitat Taylor SL, Hefle SL. Ingredient and labeling issues associated with allergenic foods. Allergy. 2001; 56 Suppl. 67: 64–9PubMedCrossRef Taylor SL, Hefle SL. Ingredient and labeling issues associated with allergenic foods. Allergy. 2001; 56 Suppl. 67: 64–9PubMedCrossRef
24.
Zurück zum Zitat LeWitt PA, Trosch RM. Idiosyncratic reactions to intramuscular botulinum toxin type A injection. Mov Disord. 1997; 12: 1064–7PubMedCrossRef LeWitt PA, Trosch RM. Idiosyncratic reactions to intramuscular botulinum toxin type A injection. Mov Disord. 1997; 12: 1064–7PubMedCrossRef
25.
Zurück zum Zitat Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord. 1995; 10: 574–9PubMedCrossRef Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord. 1995; 10: 574–9PubMedCrossRef
26.
Zurück zum Zitat Malnick SD, Metchnik L, Somin M, et al. Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol. 2000; 95: 3333–4PubMedCrossRef Malnick SD, Metchnik L, Somin M, et al. Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol. 2000; 95: 3333–4PubMedCrossRef
27.
Zurück zum Zitat Tsuboi M, Furukawa Y, Kurogouchi F, et al. Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart. Jpn J Pharmacol. 2002; 89: 249–54PubMedCrossRef Tsuboi M, Furukawa Y, Kurogouchi F, et al. Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart. Jpn J Pharmacol. 2002; 89: 249–54PubMedCrossRef
28.
Zurück zum Zitat Wollina U. Botulinum A toxin for wrinkles: release from tension headache. J Fur Acad Dermatol Venereol. 2000; 14: 142–3CrossRef Wollina U. Botulinum A toxin for wrinkles: release from tension headache. J Fur Acad Dermatol Venereol. 2000; 14: 142–3CrossRef
29.
Zurück zum Zitat Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a safe migraine preventive treatment. Headache. 2000; 40: 445–50PubMedCrossRef Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a safe migraine preventive treatment. Headache. 2000; 40: 445–50PubMedCrossRef
30.
Zurück zum Zitat Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg. 2004; 52: 442–7PubMedCrossRef Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg. 2004; 52: 442–7PubMedCrossRef
31.
Zurück zum Zitat Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. J Am Acad Dermatol. 2002; 46: 62–5PubMedCrossRef Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. J Am Acad Dermatol. 2002; 46: 62–5PubMedCrossRef
32.
Zurück zum Zitat Goldman A. Botulinum toxin in plastic surgery: experience and indications in 1200 treated areas. Rev Soc Bras Cir Past Sao Paulo. 1999; 14: 21–30 Goldman A. Botulinum toxin in plastic surgery: experience and indications in 1200 treated areas. Rev Soc Bras Cir Past Sao Paulo. 1999; 14: 21–30
33.
Zurück zum Zitat Hexsel D, Mazzuco R, Zechmeister M, et al. Complications and adverse effects: diagnosis and treatment. In: Hexsel D, Trinidade de Almeida A, editors. Cosmetic use of botulinum toxin. Porto Alegre: AGE Editoria, 2002: 233–9 Hexsel D, Mazzuco R, Zechmeister M, et al. Complications and adverse effects: diagnosis and treatment. In: Hexsel D, Trinidade de Almeida A, editors. Cosmetic use of botulinum toxin. Porto Alegre: AGE Editoria, 2002: 233–9
34.
Zurück zum Zitat Fiacchino F, Grandi L, Soliveri P, et al. Sensitivity to vecuronium after botulinum toxin administration. J Neurosurg Anesthesiol. 1997; 9: 149–53PubMedCrossRef Fiacchino F, Grandi L, Soliveri P, et al. Sensitivity to vecuronium after botulinum toxin administration. J Neurosurg Anesthesiol. 1997; 9: 149–53PubMedCrossRef
35.
Zurück zum Zitat Matarasso A, Deva AK, and the American Society of Plastic Surgeons DATA Committee. Botulinum toxin. Plast Reconstr Surg. 2002; 109: 1191–7PubMedCrossRef Matarasso A, Deva AK, and the American Society of Plastic Surgeons DATA Committee. Botulinum toxin. Plast Reconstr Surg. 2002; 109: 1191–7PubMedCrossRef
36.
Zurück zum Zitat Letessier S. Treatment of wrinkles with botulinum toxin. J Dermatol Treat. 1999; 10: 31–6CrossRef Letessier S. Treatment of wrinkles with botulinum toxin. J Dermatol Treat. 1999; 10: 31–6CrossRef
37.
Zurück zum Zitat Sunness JS, Kelman S. Cosmetic Botox injection mimicking myasthenia gravis. Plast Reconstr Surg. 2004; 113: 1515PubMed Sunness JS, Kelman S. Cosmetic Botox injection mimicking myasthenia gravis. Plast Reconstr Surg. 2004; 113: 1515PubMed
38.
Zurück zum Zitat Wyndaele JJ, van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002; 40: 599–600PubMedCrossRef Wyndaele JJ, van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002; 40: 599–600PubMedCrossRef
39.
Zurück zum Zitat Dressler D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia [letter]. J Neurol Neurosurg Psychiatry. 2002; 73: 604PubMedCrossRef Dressler D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia [letter]. J Neurol Neurosurg Psychiatry. 2002; 73: 604PubMedCrossRef
40.
Zurück zum Zitat Carruthers A, Kleine K, Carruthers J. Botulinum A exotoxin in clinical dermatology. J Am Acad Dermatol. 1996; 34: 788–97PubMedCrossRef Carruthers A, Kleine K, Carruthers J. Botulinum A exotoxin in clinical dermatology. J Am Acad Dermatol. 1996; 34: 788–97PubMedCrossRef
41.
Zurück zum Zitat Carruthers J, Carruthers A. Practical cosmetic Botox techniques. J Cutan Med Surg. 1999; 3 Suppl. 4: 49–52 Carruthers J, Carruthers A. Practical cosmetic Botox techniques. J Cutan Med Surg. 1999; 3 Suppl. 4: 49–52
42.
Zurück zum Zitat Alam M, Dover JS, Klein AW, et al. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol. 2002; 138: 1243–4CrossRef Alam M, Dover JS, Klein AW, et al. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol. 2002; 138: 1243–4CrossRef
43.
44.
Zurück zum Zitat Rzany B, for the Expert Group. Botulinumtoxin A in der Asthetischen Dermatologie. Kosmetische Medizin. 2003; 24: 72–9 Rzany B, for the Expert Group. Botulinumtoxin A in der Asthetischen Dermatologie. Kosmetische Medizin. 2003; 24: 72–9
45.
Zurück zum Zitat Ahn MS, Callen M, Maas CS. Temporal brow list using botulinum toxin A. Plast Reconstr Surg. 2000; 105: 112–35 Ahn MS, Callen M, Maas CS. Temporal brow list using botulinum toxin A. Plast Reconstr Surg. 2000; 105: 112–35
46.
Zurück zum Zitat Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997; 235: 197–9PubMedCrossRef Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997; 235: 197–9PubMedCrossRef
47.
Zurück zum Zitat Lew H, Yun YS, Lee SY, et al. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica. 2002; 216: 50–4PubMedCrossRef Lew H, Yun YS, Lee SY, et al. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica. 2002; 216: 50–4PubMedCrossRef
48.
Zurück zum Zitat Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol Surg. 1998; 24: 1181–3PubMedCrossRef Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol Surg. 1998; 24: 1181–3PubMedCrossRef
49.
Zurück zum Zitat Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast Surg. 1999; 15: 225-62CrossRef Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast Surg. 1999; 15: 225-62CrossRef
50.
Zurück zum Zitat Garcia A, Fulton E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg. 1996; 22: 39–43PubMedCrossRef Garcia A, Fulton E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg. 1996; 22: 39–43PubMedCrossRef
51.
Zurück zum Zitat Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg. 2002; 26: 356–9PubMedCrossRef Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg. 2002; 26: 356–9PubMedCrossRef
52.
Zurück zum Zitat Kim DW, Cundiff J, Toriumi DM. Botulinum toxin A for the treatment of lateral periorbital rhytids. Facial Plast Surg North Am. 2003; 11: 445–51CrossRef Kim DW, Cundiff J, Toriumi DM. Botulinum toxin A for the treatment of lateral periorbital rhytids. Facial Plast Surg North Am. 2003; 11: 445–51CrossRef
53.
Zurück zum Zitat Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2003; 11: 483–92PubMedCrossRef Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2003; 11: 483–92PubMedCrossRef
54.
Zurück zum Zitat Goldman MP. Festoon formation after infraorbital botulinum A toxin: a case report. Dermatol Surg. 2003; 29: 56–61CrossRef Goldman MP. Festoon formation after infraorbital botulinum A toxin: a case report. Dermatol Surg. 2003; 29: 56–61CrossRef
55.
Zurück zum Zitat Flynn TC, Carruthers JA, Carruthers JA, et al. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg. 2003; 29: 943–51PubMedCrossRef Flynn TC, Carruthers JA, Carruthers JA, et al. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg. 2003; 29: 943–51PubMedCrossRef
56.
Zurück zum Zitat Trinidade de Almeida AR, Scuartz Cemea S. Regarding browlift with botulinum toxin [letter]. Dermatol Surg. 2001; 27: 848CrossRef Trinidade de Almeida AR, Scuartz Cemea S. Regarding browlift with botulinum toxin [letter]. Dermatol Surg. 2001; 27: 848CrossRef
57.
Zurück zum Zitat Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004; 22: 66–75PubMedCrossRef Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004; 22: 66–75PubMedCrossRef
58.
Zurück zum Zitat Jeong H, Yum K-W, Lee S-S, et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003; 29: 484–9CrossRef Jeong H, Yum K-W, Lee S-S, et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003; 29: 484–9CrossRef
59.
Zurück zum Zitat Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003; 29: 477–83PubMedCrossRef Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003; 29: 477–83PubMedCrossRef
60.
Zurück zum Zitat Kim HJ, Seo K, Yum KW, et al. Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Anton Neurosci. 2002; 102: 8–12CrossRef Kim HJ, Seo K, Yum KW, et al. Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Anton Neurosci. 2002; 102: 8–12CrossRef
61.
Zurück zum Zitat Lu L, Atchabahian A, Mackinnon SE, et al. Nerve injury with botulinum toxin. Plast Reconstr Surg. 1998; 101: 1875–80PubMedCrossRef Lu L, Atchabahian A, Mackinnon SE, et al. Nerve injury with botulinum toxin. Plast Reconstr Surg. 1998; 101: 1875–80PubMedCrossRef
62.
Zurück zum Zitat Burguera JA, Villaroya T, Lopez-Alemany M. Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 2000; 23: 226–8PubMedCrossRef Burguera JA, Villaroya T, Lopez-Alemany M. Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 2000; 23: 226–8PubMedCrossRef
63.
Zurück zum Zitat Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. Vet Hum Toxicol. 2000; 42: 163PubMed Cobb DB, Watson WA, Fernandez MC. Botulism-like syndrome after injections of botulinum toxin. Vet Hum Toxicol. 2000; 42: 163PubMed
64.
Zurück zum Zitat Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Janckovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 3–13 Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Janckovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 3–13
65.
Zurück zum Zitat De Groot M, Schubert M, Rothe B, et al. Zentrale Effekte von Botulinumtoxin Typ A. Klin Neurophysiol. 2002; 33: 207–12CrossRef De Groot M, Schubert M, Rothe B, et al. Zentrale Effekte von Botulinumtoxin Typ A. Klin Neurophysiol. 2002; 33: 207–12CrossRef
66.
Zurück zum Zitat Murray C, Solish N. Metallic taste: an unusual reaction to botulinum toxin A. Dermatol Surg. 2003; 29: 562–3PubMedCrossRef Murray C, Solish N. Metallic taste: an unusual reaction to botulinum toxin A. Dermatol Surg. 2003; 29: 562–3PubMedCrossRef
67.
Zurück zum Zitat Dressler D, Münchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increasing botulinum toxin doses? Eur Neurol; 2002; 47: 118–21PubMedCrossRef Dressler D, Münchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increasing botulinum toxin doses? Eur Neurol; 2002; 47: 118–21PubMedCrossRef
68.
Zurück zum Zitat Carruthers A, Carruthers J. Update on the botulinum neurotoxins. Skin Therapy Lett. 2001; 6: 1–2PubMed Carruthers A, Carruthers J. Update on the botulinum neurotoxins. Skin Therapy Lett. 2001; 6: 1–2PubMed
69.
Zurück zum Zitat Wutthipan S, Kowal L, O’Day J, et al. Diplopia following subcutaneous injections of botulinum toxin A toxin for facial spasms. J Pediatr Ophthalmol Strabismus. 1997; 34: 229–34 Wutthipan S, Kowal L, O’Day J, et al. Diplopia following subcutaneous injections of botulinum toxin A toxin for facial spasms. J Pediatr Ophthalmol Strabismus. 1997; 34: 229–34
70.
Zurück zum Zitat Heckmann M, Rzany. Botulinumtoxin in der Dermatologie. Grundlagen and praktische Anwendung. München: Urban & Vogel-Medizin & Wissen, 2002 Heckmann M, Rzany. Botulinumtoxin in der Dermatologie. Grundlagen and praktische Anwendung. München: Urban & Vogel-Medizin & Wissen, 2002
71.
Zurück zum Zitat Scott AB. Preventing ptosis after botulinum treatment. Ophthal Plast Reconstr Surg. 1997; 13: 81–3PubMedCrossRef Scott AB. Preventing ptosis after botulinum treatment. Ophthal Plast Reconstr Surg. 1997; 13: 81–3PubMedCrossRef
72.
Zurück zum Zitat Driezen NG, Framn L. Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol. 1989; 107: 85–6 Driezen NG, Framn L. Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol. 1989; 107: 85–6
73.
Zurück zum Zitat Teimourian B. Blindness following fat injection. Plast Reconstr Surg. 1988; 92: 361 Teimourian B. Blindness following fat injection. Plast Reconstr Surg. 1988; 92: 361
74.
Zurück zum Zitat Sahlin S, Chen E, Kaugessar T, et al. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000; 129: 481–6PubMedCrossRef Sahlin S, Chen E, Kaugessar T, et al. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000; 129: 481–6PubMedCrossRef
75.
Zurück zum Zitat Matarasso SL. Decreased tear expression with an abnormal Schirmer’s test following botulinum toxin type A for the treatment of lateral canthal rhytides. Dermatol Surg. 2002; 28: 149–52PubMedCrossRef Matarasso SL. Decreased tear expression with an abnormal Schirmer’s test following botulinum toxin type A for the treatment of lateral canthal rhytides. Dermatol Surg. 2002; 28: 149–52PubMedCrossRef
76.
Zurück zum Zitat Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride solution with and without preservative. Arch Dermatol. 2002; 138: 510–4PubMedCrossRef Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride solution with and without preservative. Arch Dermatol. 2002; 138: 510–4PubMedCrossRef
77.
Zurück zum Zitat Söylev MF, Kocak N, Kuvaki B, et al. Anesthesia with EMLA® cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002; 216: 355–8PubMedCrossRef Söylev MF, Kocak N, Kuvaki B, et al. Anesthesia with EMLA® cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002; 216: 355–8PubMedCrossRef
78.
Zurück zum Zitat Linder JS, Edmonson BC, Laquis SJ, et al. Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg. 2002; 6: 441–2CrossRef Linder JS, Edmonson BC, Laquis SJ, et al. Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg. 2002; 6: 441–2CrossRef
79.
Zurück zum Zitat Harth W, Linse R. Botulinophilia: contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther. 2001; 39: 460–3PubMed Harth W, Linse R. Botulinophilia: contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther. 2001; 39: 460–3PubMed
80.
Zurück zum Zitat Brenner R, Madhusoodanan S, Kom Z, et al. Acute anxiety and depression induced by loss of sensations and muscle control after botulinum toxin A injection. South Med J. 1999; 92: 738PubMedCrossRef Brenner R, Madhusoodanan S, Kom Z, et al. Acute anxiety and depression induced by loss of sensations and muscle control after botulinum toxin A injection. South Med J. 1999; 92: 738PubMedCrossRef
81.
Zurück zum Zitat Roehm PC, Perry JD, Girkin CA, et al. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuroophthalmol. 1999; 19: 7–9PubMedCrossRef Roehm PC, Perry JD, Girkin CA, et al. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuroophthalmol. 1999; 19: 7–9PubMedCrossRef
82.
Zurück zum Zitat Karpati S, Desaknai S, Desaknai M, et al. Human herpesvirus type 8-positive facial angiosarcoma developing at the site of botulinum toxin injection for blepharospasm. Br J Dermatol. 2000; 143: 660–2PubMedCrossRef Karpati S, Desaknai S, Desaknai M, et al. Human herpesvirus type 8-positive facial angiosarcoma developing at the site of botulinum toxin injection for blepharospasm. Br J Dermatol. 2000; 143: 660–2PubMedCrossRef
83.
Zurück zum Zitat Latimer PR, Hodgkins PR, Vakalis AN, et al. Necrotising fasciitis as a complication of botulinum toxin injection. Eye. 1998; 12: 51–3PubMedCrossRef Latimer PR, Hodgkins PR, Vakalis AN, et al. Necrotising fasciitis as a complication of botulinum toxin injection. Eye. 1998; 12: 51–3PubMedCrossRef
84.
Zurück zum Zitat Bowden JB, Rapini RP. Psoriasiform eruption from intramuscular botulinum A toxin. Cutis. 1992; 50: 415–6PubMed Bowden JB, Rapini RP. Psoriasiform eruption from intramuscular botulinum A toxin. Cutis. 1992; 50: 415–6PubMed
85.
Zurück zum Zitat Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998; 24: 1184–6PubMedCrossRef Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998; 24: 1184–6PubMedCrossRef
Metadaten
Titel
Managing Adverse Events Associated with Botulinum Toxin Type A
A Focus on Cosmetic Procedures
verfasst von
Dr Uwe Wollina
Helga Konrad
Publikationsdatum
01.06.2005
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2005
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200506030-00001

Weitere Artikel der Ausgabe 3/2005

American Journal of Clinical Dermatology 3/2005 Zur Ausgabe

Therapy in Practice

Lentigo Maligna

Adis Drug Profile

Imiquimod

Adis Drug Profile

Imiquimod

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.